{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:07:21Z","timestamp":1792098441160,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NO1-CM-62209"],"award-info":[{"award-number":["NO1-CM-62209"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["K12CA138464"],"award-info":[{"award-number":["K12CA138464"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00280-018-3553-4","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T05:52:20Z","timestamp":1520488340000},"page":"957-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9053-3841","authenticated-orcid":false,"given":"Anthony B.","family":"El-Khoueiry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Semrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Bahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"3553_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"3553_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334","journal-title":"Lancet Oncol"},{"key":"3553_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc1387","volume":"4","author":"MN Pollak","year":"2004","unstructured":"Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505\u2013518","journal-title":"Nat Rev Cancer"},{"key":"3553_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/excr.1999.4667","volume":"253","author":"R Baserga","year":"1999","unstructured":"Baserga R (1999) The IGF-I receptor in cancer research. Exp Cell Res 253:1\u20136","journal-title":"Exp Cell Res"},{"key":"3553_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/sj.bjc.6600777","volume":"88","author":"N Sedlaczek","year":"2003","unstructured":"Sedlaczek N, Hasilik A, Neuhaus P, Schuppan D, Herbst H (2003) Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer 88:733\u2013739","journal-title":"Br J Cancer"},{"key":"3553_CR6","first-page":"1725","volume":"10","author":"AT De Souza","year":"1995","unstructured":"De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL (1995) Frequent loss of heterozygosity on 6q at the mannose 6-phosphate\/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10:1725\u20131729","journal-title":"Oncogene"},{"key":"3553_CR7","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.3748\/wjg.v12.i25.3977","volume":"12","author":"YC Zhang","year":"2006","unstructured":"Zhang YC, Wang XP, Zhang LY, Song AL, Kou ZM, Li XS (2006) Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 12:3977\u20133982","journal-title":"World J Gastroenterol"},{"key":"3553_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.bcp.2006.02.006","volume":"71","author":"M Hopfner","year":"2006","unstructured":"Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H (2006) Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 71:1435\u20131448","journal-title":"Biochem Pharmacol"},{"key":"3553_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1872-034X.2007.00055.x","volume":"37","author":"RX Lin","year":"2007","unstructured":"Lin RX, Wang ZY, Zhang N, Tuo CW, Liang QD, Sun YN et al (2007) Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model. Hepatol Res 37:366\u2013375","journal-title":"Hepatol Res"},{"key":"3553_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1538-7836.2007.02431.x","volume":"5","author":"R Granata","year":"2007","unstructured":"Granata R, Trovato L, Lupia E, Sala G, Settanni F, Camussi G et al (2007) Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost 5:835\u2013845","journal-title":"J Thromb Haemost"},{"key":"3553_CR11","first-page":"8912","volume":"63","author":"D Burtrum","year":"2003","unstructured":"Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912\u20138921","journal-title":"Cancer Res"},{"key":"3553_CR12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jhep.2010.01.015","volume":"52","author":"V Tovar","year":"2010","unstructured":"Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M et al (2010) IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52:550\u2013559","journal-title":"J Hepatol"},{"key":"3553_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"3553_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jhep.2013.09.008","volume":"60","author":"GK Abou-Alfa","year":"2014","unstructured":"Abou-Alfa GK, Capanu M, O\u2019Reilly EM, Ma J, Chou JF, Gansukh B et al (2014) A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol 60:319\u2013324","journal-title":"J Hepatol"},{"key":"3553_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","volume":"33","author":"C Cainap","year":"2015","unstructured":"Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y et al (2015) Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33:172\u2013179","journal-title":"J Clin Oncol"},{"key":"3553_CR16","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"AL Cheng","year":"2013","unstructured":"Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S et al (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31:4067\u20134075","journal-title":"J Clin Oncol"},{"key":"3553_CR17","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA et al (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517\u20133524","journal-title":"J Clin Oncol"},{"key":"3553_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","volume":"33","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ et al (2015) SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 33:559\u2013566","journal-title":"J Clin Oncol"},{"key":"3553_CR19","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-12-2791","volume":"19","author":"L Goyal","year":"2013","unstructured":"Goyal L, Muzumdar MD, Zhu AX (2013) Targeting the HGF\/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 19:2310\u20132318","journal-title":"Clin Cancer Res"},{"key":"3553_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejso.2006.12.007","volume":"34","author":"GY Chau","year":"2008","unstructured":"Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL et al (2008) Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol 34:333\u2013338","journal-title":"Eur J Surg Oncol"},{"key":"3553_CR21","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s13277-013-1308-8","volume":"35","author":"S Karabulut","year":"2014","unstructured":"Karabulut S, Tas F, Akyuz F, Ormeci AC, Serilmez M, Soydinc HO et al (2014) Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma. Tumour Biol 35:2327\u20132333","journal-title":"Tumour Biol"},{"key":"3553_CR22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s00535-004-1469-8","volume":"39","author":"P Vejchapipat","year":"2004","unstructured":"Vejchapipat P, Tangkijvanich P, Theamboonlers A, Chongsrisawat V, Chittmittrapap S, Poovorawan Y (2004) Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 39:1182\u20131188","journal-title":"J Gastroenterol"},{"key":"3553_CR23","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/1535-7163.MCT-05-0175","volume":"5","author":"TW Bauer","year":"2006","unstructured":"Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP et al (2006) Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 5:1676\u20131682","journal-title":"Mol Cancer Ther"},{"key":"3553_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1053\/jhep.2002.36158","volume":"36","author":"JA Price","year":"2002","unstructured":"Price JA, Kovach SJ, Johnson T, Koniaris LG, Cahill PA, Sitzmann JV et al (2002) Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology 36:1089\u20131097","journal-title":"Hepatology"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3553-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:33:55Z","timestamp":1589628835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3553-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3553-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,8]]},"assertion":[{"value":"2 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Anthony El-Khoueiry and Dr. Heinz-Josef Lenz both have received honoraria for advisory board participation from Bayer. No potential conflicts of interest were disclosed by other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}